Ensign Peak Advisors Inc Reduces Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Ensign Peak Advisors Inc lessened its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 274,500 shares of the medical device company's stock after selling 3,813 shares during the quarter. Ensign Peak Advisors Inc owned 0.07% of DexCom worth $21,348,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in DXCM. Private Trust Co. NA raised its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares in the last quarter. Optiver Holding B.V. acquired a new stake in DexCom during the fourth quarter worth about $33,000. TD Private Client Wealth LLC grew its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $38,000. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at $22,063,918.86. This trade represents a 4.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock valued at $4,734,384 over the last quarter. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on DXCM. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Canaccord Genuity Group boosted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Citigroup boosted their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.11.

DexCom Price Performance

DXCM traded up $2.41 during midday trading on Wednesday, hitting $86.52. The stock had a trading volume of 3,826,434 shares, compared to its average volume of 4,348,658. The company has a market cap of $33.93 billion, a P/E ratio of 60.50, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The business has a fifty day moving average of $71.23 and a 200 day moving average of $77.35. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 EPS. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.